176 related articles for article (PubMed ID: 32265108)
1. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis.
Tsilimigras DI; Moris D; Mehta R; Paredes AZ; Sahara K; Guglielmi A; Aldrighetti L; Weiss M; Bauer TW; Alexandrescu S; Poultsides GA; Maithel SK; Marques HP; Martel G; Pulitano C; Shen F; Soubrane O; Koerkamp BG; Endo I; Pawlik TM
HPB (Oxford); 2020 Dec; 22(12):1667-1674. PubMed ID: 32265108
[TBL] [Abstract][Full Text] [Related]
2. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
3. Inflammatory markers in intrahepatic cholangiocarcinoma: Effects of advanced liver disease.
Sellers CM; Uhlig J; Ludwig JM; Stein SM; Kim HS
Cancer Med; 2019 Oct; 8(13):5916-5929. PubMed ID: 31429524
[TBL] [Abstract][Full Text] [Related]
4. Investigating effects of preoperative inflammatory biomarkers on predicting survival outcomes of intrahepatic cholangiocarcinoma after curative resection.
Zhang Z; Zhou Y; Hu K; Huang Y
World J Surg Oncol; 2020 Oct; 18(1):272. PubMed ID: 33097053
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma.
Terasaki F; Sugiura T; Okamura Y; Ito T; Yamamoto Y; Ashida R; Ohgi K; Uesaka K
Surg Today; 2021 Oct; 51(10):1602-1609. PubMed ID: 34142236
[TBL] [Abstract][Full Text] [Related]
7. [The Predictive Value of Perioperative Inflammatory Indicatorsin Prognosis of the Intrahepatic Cholangiocarcinoma Patients after Hepatectomy].
Zhang ZF; Wang T; Kong JJ; Yang LP; Yang XW; Wang WT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2020 May; 51(3):403-410. PubMed ID: 32543151
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium.
Toyoda J; Sahara K; Maithel SK; Abbott DE; Poultsides GA; Wolfgang C; Fields RC; He J; Scoggins C; Idrees K; Shen P; Endo I; Pawlik TM
Ann Surg Oncol; 2022 Nov; 29(12):7605-7614. PubMed ID: 35768667
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma.
Tsilimigras DI; Mehta R; Aldrighetti L; Poultsides GA; Maithel SK; Martel G; Shen F; Koerkamp BG; Endo I; Pawlik TM;
J Am Coll Surg; 2020 Apr; 230(4):381-391.e2. PubMed ID: 32014569
[TBL] [Abstract][Full Text] [Related]
10. Effects of Preoperative Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios on Survival in Patients with Extrahepatic Cholangiocarcinoma.
Kitano Y; Yamashita YI; Yamamura K; Arima K; Kaida T; Miyata T; Nakagawa S; Mima K; Imai K; Hashimoto D; Chikamoto A; Baba H
Anticancer Res; 2017 Jun; 37(6):3229-3237. PubMed ID: 28551669
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of preoperative inflammatory markers in patients with intrahepatic cholangiocarcinoma after hepatic resection: A systematic review and meta-analysis.
Cui H; Li Y; Li S; Liu G
Cancer Med; 2023 Jan; 12(1):99-110. PubMed ID: 35692190
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study.
Zhu J; Wang D; Liu C; Huang R; Gao F; Feng X; Lan T; Li H; Wu H
Front Immunol; 2023; 14():1165510. PubMed ID: 37063918
[TBL] [Abstract][Full Text] [Related]
13. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
Front Immunol; 2021; 12():691364. PubMed ID: 34248983
[TBL] [Abstract][Full Text] [Related]
14. The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma.
Buettner S; Spolverato G; Kimbrough CW; Alexandrescu S; Marques HP; Lamelas J; Aldrighetti L; Gamblin TC; Maithel SK; Pulitano C; Weiss M; Bauer TW; Shen F; Poultsides GA; Marsh JW; IJzermans JNM; Koerkamp BG; Pawlik TM
Surgery; 2018 Sep; 164(3):411-418. PubMed ID: 29903509
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
16. The elevated preoperative neutrophil-to-lymphocyte ratio predicts poor prognosis in intrahepatic cholangiocarcinoma patients undergoing hepatectomy.
Chen Q; Yang LX; Li XD; Yin D; Shi SM; Chen EB; Yu L; Zhou ZJ; Zhou SL; Shi YH; Fan J; Zhou J; Dai Z
Tumour Biol; 2015 Jul; 36(7):5283-9. PubMed ID: 25672606
[TBL] [Abstract][Full Text] [Related]
17. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.
Lolli C; Caffo O; Scarpi E; Aieta M; Conteduca V; Maines F; Bianchi E; Massari F; Veccia A; Chiuri VE; Facchini G; De Giorgi U
Front Pharmacol; 2016; 7():376. PubMed ID: 27790145
[No Abstract] [Full Text] [Related]
18. Prognostic value of systemic ımmune ınflammation ındex in patients with laryngeal cancer.
Atasever Akkas E; Yucel B
Eur Arch Otorhinolaryngol; 2021 Jun; 278(6):1945-1955. PubMed ID: 33837464
[TBL] [Abstract][Full Text] [Related]
19. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab.
Jiang L; Fang J; Ding J
Cancer Manag Res; 2020; 12():475-484. PubMed ID: 32021460
[TBL] [Abstract][Full Text] [Related]
20. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
